Literature DB >> 6292342

Involvement of natural killer cells in the pathogenesis of murine cytomegalovirus interstitial pneumonitis and the immune response to infection.

G V Quinnan, J F Manischewitz, N Kirmani.   

Abstract

The significance of the natural killer (NK) cell response to murine cytomegalovirus (MCMV) infection was evaluated in C3H/HeN mice. This strain was selected for study after preliminary demonstration that the NK cell response, occurring between 3 and 6 days post-infection was relatively high in comparison to other mouse strains studied. A dose-response effect of hydrocortisone treatment on suppression of this response was found. A dose of hydrocortisone, given subcutaneously on two successive days, which was found to markedly inhibit the NK cell response, had no effect on development of serum interferon or antibody levels, or spleen cytotoxic T cell activity under the conditions studied. Suppression of the NK cell response by this treatment, however, was accompanied by enhanced spleen and pulmonary virus replication in vivo and increased susceptibility of mice to lethal infection. MCMV interstitial pneumonitis was characterized histologically and lung lymphocytes studied at 4 days post-infection were found to have increased NK cell activity. Treatment of mice with hydrocortisone was found to inhibit development of gross and histological evidence of pneumonitis. These findings indicate that NK cells are involved in the pathogenesis of MCMV interstitial pneumonitis and may function early in infection to restrict the extent of virus replication.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6292342     DOI: 10.1099/0022-1317-58-1-173

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

Review 1.  Animal cytomegaloviruses.

Authors:  J Staczek
Journal:  Microbiol Rev       Date:  1990-09

Review 2.  Emerging insights into human health and NK cell biology from the study of NK cell deficiencies.

Authors:  Emily M Mace; Jordan S Orange
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

3.  Restoration of immunological responses by THF, a thymic hormone, in mice infected with murine cytomegalovirus (MCMV).

Authors:  E Katorza; M Pecht; R N Apte; D Benharroch; Y Burstein; N Trainin; B Rager-Zisman
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

4.  Pathogenesis of acute murine cytomegalovirus infection in resistant and susceptible strains of mice.

Authors:  J A Mercer; D H Spector
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

5.  Therapy of a fatal murine cytomegalovirus infection with thymic humoral factor (THF-gamma 2) treated immune spleen cells.

Authors:  B Rager-Zisman; F Zuckerman; D Benharroch; M Pecht; Y Burstein; N Trainin
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

6.  Effects of immunosuppression with cyclophosphamide on acute murine cytomegalovirus infection and virus-augmented natural killer cell activity.

Authors:  M K Selgrade; M J Daniels; P C Hu; F J Miller; J A Graham
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

7.  Occurrence and reactivation of latent Aujeszky's disease virus following challenge in previously vaccinated pigs.

Authors:  G Wittmann; V Ohlinger; H J Rziha
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

8.  Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice.

Authors:  J F Bukowski; B A Woda; R M Welsh
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

9.  Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo.

Authors:  J F Bukowski; J F Warner; G Dennert; R M Welsh
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

10.  Pathogenesis of cytomegalovirus-associated pneumonitis in ICR mice: possible involvement of superoxide radicals.

Authors:  T Ikeda; K Shimokata; T Daikoku; T Fukatsu; Y Tsutsui; Y Nishiyama
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.